FDA approves ALXN’s Kanuma for LAL deficiency: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476013.htm The approval entitles ALXN to an FDA priority-review voucher. ALXN picked up Kanuma in the controversial $8.4B GEVA buyout in May 2015 (#msg-113395760).